• Je něco špatně v tomto záznamu ?

Adherence and blood pressure control in patients with primary aldosteronism

TMP. Nikrýnová Nguyen, B. Štrauch, O. Petrák, Z. Krátká, R. Holaj, I. Kurcová, V. Marešová, A. Pilková, J. Hartinger, P. Waldauf, T. Zelinka, J. Widimský

. 2022 ; 31 (1) : 58-63. [pub] -

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22017731

PURPOSE: The aim of our study was to evaluate the adherence to mineralocorticoid receptor (MR) antagonists and other antihypertensive therapy and blood pressure control in conservatively treated patients with primary aldosteronism (PA). MATERIALS AND METHODS: Conservatively treated subjects with previously confirmed PA (n-50, 64.5 ± 9 years of age, 24% women) were investigated via our outpatient hypertension clinic. All subjects underwent regular examinations in our clinic. In addition to basic laboratory and clinical parameters, 24 h ambulatory blood pressure monitoring (ABPM) (Spacelabs) was evaluated. Unplanned blood sampling for assessment of serum antihypertensive drug concentrations by the means of liquid chromatography-mass spectrometry was performed in all patients. In case of spironolactone, its active metabolite canrenone was also evaluated. Total non-compliance was then defined as the absence of all measured antihypertensive drugs. Partial non-compliance was calculated as the absence of serum levels of at least one, but not all antihypertensive drugs prescribed. RESULTS: Good blood pressure control was detected (mean 24 h systolic/diastolic BP 130 ± 12/77 ± 9 mmHg). The average number of antihypertensive drugs was 3.9 ± 1.5. All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 ± 20 mg) and in the remaining 56% of subjects eplerenone was administered (average daily dose 80 ± 30 mg) due to spironolactone side effects. Assessment of antihypertensive drug concentrations revealed full adherence in 80% of all subjects, partial nonadherence was noted in the remaining 20% of subjects. MR antagonist levels were detected in almost all subjects (49 out of 50). CONCLUSIONS: Good blood pressure control and adherence to therapy were detected in conservatively treated patients with PA. Eplerenone had to be used quite often as male subjects did not tolerate dose escalation due to spironolactone side effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017731
003      
CZ-PrNML
005      
20240522100022.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1080/08037051.2022.2061416 $2 doi
035    __
$a (PubMed)35438025
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Nikrýnová Nguyen, Thi Minh Phuong $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
245    10
$a Adherence and blood pressure control in patients with primary aldosteronism / $c TMP. Nikrýnová Nguyen, B. Štrauch, O. Petrák, Z. Krátká, R. Holaj, I. Kurcová, V. Marešová, A. Pilková, J. Hartinger, P. Waldauf, T. Zelinka, J. Widimský
520    9_
$a PURPOSE: The aim of our study was to evaluate the adherence to mineralocorticoid receptor (MR) antagonists and other antihypertensive therapy and blood pressure control in conservatively treated patients with primary aldosteronism (PA). MATERIALS AND METHODS: Conservatively treated subjects with previously confirmed PA (n-50, 64.5 ± 9 years of age, 24% women) were investigated via our outpatient hypertension clinic. All subjects underwent regular examinations in our clinic. In addition to basic laboratory and clinical parameters, 24 h ambulatory blood pressure monitoring (ABPM) (Spacelabs) was evaluated. Unplanned blood sampling for assessment of serum antihypertensive drug concentrations by the means of liquid chromatography-mass spectrometry was performed in all patients. In case of spironolactone, its active metabolite canrenone was also evaluated. Total non-compliance was then defined as the absence of all measured antihypertensive drugs. Partial non-compliance was calculated as the absence of serum levels of at least one, but not all antihypertensive drugs prescribed. RESULTS: Good blood pressure control was detected (mean 24 h systolic/diastolic BP 130 ± 12/77 ± 9 mmHg). The average number of antihypertensive drugs was 3.9 ± 1.5. All subjects were treated by MR antagonists. 44% of patients received spironolactone (average daily dose 45 ± 20 mg) and in the remaining 56% of subjects eplerenone was administered (average daily dose 80 ± 30 mg) due to spironolactone side effects. Assessment of antihypertensive drug concentrations revealed full adherence in 80% of all subjects, partial nonadherence was noted in the remaining 20% of subjects. MR antagonist levels were detected in almost all subjects (49 out of 50). CONCLUSIONS: Good blood pressure control and adherence to therapy were detected in conservatively treated patients with PA. Eplerenone had to be used quite often as male subjects did not tolerate dose escalation due to spironolactone side effects.
650    _2
$a senioři $7 D000368
650    _2
$a antihypertenziva $7 D000959
650    _2
$a krevní tlak $7 D001794
650    _2
$a ambulantní monitorování krevního tlaku $7 D018660
650    _2
$a eplerenon $x farmakologie $x terapeutické užití $7 D000077545
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a hyperaldosteronismus $x farmakoterapie $7 D006929
650    12
$a hypertenze $x farmakoterapie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a antagonisté mineralokortikoidních receptorů $x farmakologie $x terapeutické užití $7 D000451
650    _2
$a spironolakton $x terapeutické užití $7 D013148
655    _2
$a časopisecké články $7 D016428
700    1_
$a Štrauch, Branislav $u Medica JM s.r.o, Prague, Czech Republic
700    1_
$a Petrák, Ondřej $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Krátká, Zuzana $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Holaj, Robert $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Kurcová, Ivana $u Institute of Forensic Medicine and Toxicology, Toxicology Laboratory, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Marešová, Věra $u Institute of Forensic Medicine and Toxicology, Toxicology Laboratory, General University Hospital, First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Pilková, Alena $u Department of Clinical Pharmacology and Pharmacy, First Faculty of Medicine, Institute of Pharmacology, Charles University and General University Hospital, Prague, Czech Republic
700    1_
$a Hartinger, Jan $u Department of Clinical Pharmacology and Pharmacy, First Faculty of Medicine, Institute of Pharmacology, Charles University and General University Hospital, Prague, Czech Republic $7 xx0224709
700    1_
$a Waldauf, Petr $u Department of Anesthesiology and Intensive Care Medicine, Third Faculty of Medicine and FNKV University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Zelinka, Tomáš $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Widimský, Jiří $u Third Internal Department of Endocrinology and Metabolism, General University Hospital, Charles University, Prague, Czech Republic
773    0_
$w MED00000810 $t Blood pressure $x 1651-1999 $g Roč. 31, č. 1 (2022), s. 58-63
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35438025 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20240522100018 $b ABA008
999    __
$a ok $b bmc $g 1821731 $s 1168974
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 31 $c 1 $d 58-63 $e - $i 1651-1999 $m Blood pressure $n Blood Press $x MED00000810
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace